Eileen Vergara

• Launched Springworks' first commercial product in Rare Disease Oncology, OGSIVEO (nirogacestat), for patients with progressing desmoid tumors.
• Executed strategic territory business plans for South Los Angeles, North Orange County, and Hawaii, managing complex academic and community accounts, including Kaiser Permanente, to enhance market presence.
• Built and strengthened relationships with oncology and sarcoma stakeholders, key decision makers across the territory, with an emphasis on identifying patients, removing barriers and supporting appropriate utilization of OGSIVEO.
• Collaborated with Senior Leadership, Marketing, Medical Affairs, and Market Access to successfully launch OGSIVEO and drive overall territory performance.
• Created OGSIVEO AE Management Guide to enhance patient experience and position OGSIVEO as preferred therapy for desmoid tumors.

Noteworthy Achievements

• #4 National Rank, 2024
• #6 National Rank, 2025; YTD % Average Goal Attainment 106.43%
• National Winner- Q2 2025 Growth Contest, achieving 46% growth
• # 2 National Rank Q3 2025- YTD Circle of Excellence

• Drove portfolio sales in Greater Los Angeles, and North Orange County by positioning BAVENCIO (avelumab) and TEPMETKO (tepotinib) as the preferred therapy across all approved indications in academic and community Oncology accounts, Kaiser Permanente and government accounts (County, VA).

BAVENCIO (avelumab)- IV PDL1 indicated for metastatic merkel cell (MCC), urothelial Ca (UC), renal cell Ca (RCC).

TEPMETKO (tepotinib) - Oral kinase inhibitor indicated for the treatment of adult patients with non-small cell lung Ca (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

• Successfully launched- BAVENCIO in Renal Cell Ca (2019), and Urothelial Ca (2020) with Pfizer Oncology, TEPMETKO (2021).
• Managed key accounts including UCLA, USC, Cedars Sinai, City of Hope, VA Health System, Los Angeles County DHS, The Oncology Institute of Hope to drive therapy adoption.
• Established strong relationships with oncology key opinion leaders and stakeholders across GU and Thoracic oncology including physicians, pharmacy directors, nursing directors, and other treatment decision makers.
• Leveraged clinical knowledge and customer insights to identify opportunities and address barriers for targeted oncology therapy adoption.
• Partnered cross-functionally with medical, marketing, market access, regional, and corporate teams to implement territory strategies.
• Worked extensively with Marketing on projects i.e. developing community and academic messaging, customer segmentation, patient and clinical support materials.
• Promoted Associate Director, US Oncology Marketing and HCP Lead for BAVENCIO.

Noteworthy Achievements

• President's Club, National Award Winner, 2020
• #4 National Rank (BAVENCIO), 2020
• AAA Individual Performance Rating- highest performance ranking; only rep awarded AAA rating in the nation.
• 'Raising the Bar' National Award Winner, 2019
• Selected as the Lead for National Field Advisory Ad board working directly with National Sales Leader.
• Selected as Co-Lead for Women in Leadership, field- based committee.

• Developed HCP promotional tactics and relevant sales training for new assets, updating BAVENCIO CVA with follow-up OS data from GU ASCO 2022 and creating interactive visual aid, dosing and treatment guide, nursing and HCP speaker decks, expert opinion papers, and HCP-patient dialogue tool to enhance understanding of maintenance therapy.
• Established strong relationships within the Alliance Pfizer Oncology team and EMD cross-functional team including Medical, Legal and Regulatory, Opinion Leader Liaisons and Sales leadership.
• Conducted meetings to lead tactical planning for the 2022 Brand Plan in collaboration with cross-functional team.
• Led BAVENCIO Segmentation Initiative with cross-functional team, creating deliverables for the field sales team, including Segmentation Roadmap and Objection Handler.
• Oversaw cross-functional alliance budget with Pfizer Oncology counterparts, advising on reallocations and supporting buy-up request creation.
• Organized community ad board and steering committee to collect essential insights from HCPs for BAVENCIO strategy.
• Drove BAVENCIO Marketing presentations and programming at National POA Q4 2021.

• Utilized clinical experience and expertise to promote sales of Novartis Oncology solid tumor portfolio.

SANDOSTATIN LAR (octreotide acetate): IM injection for the treatment of acromegaly and neuroendocrine tumors.

AFINITOR (everolimus): Oral mTOR inhibitor for treatment of Advanced HR+ Breast Cancer, Pancreatic Neuroendocrine tumors, Advanced Renal Cell.

ZYKADIA (ceritinib): Oral kinase inhibitor ALK+ metastatic NSCLC

KISQALI (ribociclib): Oral CDK4/6 inhibitor for HR+ Her2- breast Ca.

TAFLINAR (dabrafenib) and MEKINIST (trametinib): Oral BRAF and MEK inhibitor Advanced melanoma

VOTRIENT (pazopanib): Oral TKI for advanced Renal Cell Ca, and Soft Tissue Sarcoma

• Focused on building relationships with key accounts to drive growth.
• Delivered branded and unbranded disease state education through roundtable discussions, in-services, and formal presentations, improving clinician knowledge and patient care.
• Key Accounts: Cedars Sinai, UCLA, USC, City of Hope, UCI, DHS Accounts, VA Health Systems, UCSD, Sharp, Scripps, Kaiser Permanente.
• Collaborated with Regional District manager, sales team, regional marketers, and healthcare system account manager to identify account needs and implement initiatives for growth.
• Mentored and trained newly hired Nurse Educators
• Worked closely with Breast, NET, and Lung Marketing teams to develop educational resources for clinicians and patients.

Noteworthy Achievements

• President's Club, National Award, 2015
• Ranked #2 out of 40 Clinical Educators, Year End Award, 2014
• Peer Leadership Award, 2016
• National Impact Award, Nomination by Regional Sales Director, 2015
• Hall of Fame for Customer Care Awards, 2014
• Promotion to Senior Clinical Educator, 2014

• Managed high-volume practice for Medical Director of Radiation Oncology, coordinating care and educating patients on cancer diagnosis, therapy, and symptom management to enhance patient understanding and compliance.
• Delivered direct nursing care for adult and pediatric patients requiring anesthesia for immobilization during daily radiation treatment, ensuring safe and effective patient experiences.
• Oversaw daily staff and patient assignments as Charge Nurse, mentored new staff, interviewed potential employees, and revised educational materials and procedural instructions for patients and nursing documentation in Genitourinary Oncology program.
• Provided key support for the development and implementation of EMR. Collaborated with IT to improve and tailor nursing documentation.

• Supervised patient care delivery as charge nurse, enforcing standards of care and hospital policies, coordinating daily activities of 20-bed unit, and mentoring new nursing graduates.
• Provided nursing care to adult oncology patients post-surgical interventions (GI, ENT, Plastics, Breast, Urology, Endocrinology) in a fast-paced academic hospital, ensuring adherence to protocols and quality standards.
• Partnered with physicians and healthcare professionals to create customized treatment plans, enhancing patient outcomes through multidisciplinary collaboration.